Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06245915 · ClinicalTrials.gov registry record · Phase 1
AB-2100, an Integrated Circuit T Cell Therapy in Patients With Recurrent Clear-cell Renal Cell Carcinoma (ccRCC)
A Phase 1 study of Recurrence and Advanced/Metastatic Clear Cell Renal Cell Carcinoma, sponsored by Arsenal Biosciences.
- Active
- Registry status
- Phase 1
- Development phase
- 37
- Enrollment target
- 9
- Study locations
NCT06245915: Active Phase 1 study of Recurrence and Advanced/Metastatic Clear Cell Renal Cell Carcinoma, sponsored by Arsenal Biosciences.
NCT06245915 is a Phase 1 study of Recurrence and Advanced/Metastatic Clear Cell Renal Cell Carcinoma that is active but no longer recruiting, run by Arsenal Biosciences. The registered enrollment target is 37 participants, below the 529-participant average among 8 other Recurrence trials with a reported enrollment target (93% lower). The trial reports 9 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06245915, a Phase 1 study of Recurrence and Advanced/Metastatic Clear Cell Renal Cell Carcinoma, is active but no longer recruiting, sponsored by Arsenal Biosciences.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 37 participants
- Enrollment target
- 9
- Study locations
Study Summary
This is a multi-center, open-label phase 1/2 trial evaluating the safety and efficacy of AB-2100 cell product. The study may enroll approximately 60 patients in phase 1 and approximately 70 patients in phase 2.
Primary Outcome
Defined as dose-limiting toxicities based on a 3+3 dose escalation study design
Conditions Studied
Interventions
- BIOLOGICAL AB-2100
Study Locations (9)
New York
- Perlmutter Cancer Center - NYU Langone Health - New York
- Memorial Sloan Kettering Cancer Center - New York
Arizona
- Mayo Clinic Hospital - Phoenix
California
- City of Hope - Duarte
Florida
- Moffitt Cancer Center - Tampa
Iowa
- University of Iowa and Holden Comprehensive Cancer Center - Iowa City
Massachusetts
- Dana Farber Cancer Institue - Boston
Texas
- MD Anderson Cancer Center - Houston
Utah
- Huntsman Cancer Institute - Univ of Utah Health - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2024-02-26 |
| Est. Completion | 2028-06-30 |
| Phase | Phase 1 |
What the registry record for NCT06245915 still lists
NCT06245915 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 37 participants, a relatively small participant target, below the 529-participant average among 8 other Recurrence trials with a reported enrollment target (93% lower).
The record links to 2 conditions, with Recurrence appearing as the primary indexed condition, and to 1 intervention - of which AB-2100 is the first listed.
NCT06245915 lists 9 locations in 8 states (New York, Arizona, California).
Frequently Asked Questions
What is clinical trial NCT06245915 about?
NCT06245915 is a clinical study titled "AB-2100, an Integrated Circuit T Cell Therapy in Patients With Recurrent Clear-cell Renal Cell Carcinoma (ccRCC)". This is a multi-center, open-label phase 1/2 trial evaluating the safety and efficacy of AB-2100 cell product. The study may enroll approximately 60 patients in phase 1 and approximately 70 patients in phase 2.
What is the current status of trial NCT06245915?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 37 participants. The study started on 2024-02-26. Estimated completion is 2028-06-30.
What conditions does trial NCT06245915 study?
This clinical trial studies the following conditions: Recurrence, Advanced/Metastatic Clear Cell Renal Cell Carcinoma.
What interventions are being tested in trial NCT06245915?
The interventions under investigation include: AB-2100 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06245915?
This trial is sponsored by Arsenal Biosciences, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06245915 being conducted?
This trial has 9 study locations across Arizona, California, Florida, Iowa, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrence
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06245915's enrollment target sits among peer trials
37 8th of 8 higher than 1 of 8 other Recurrence trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Recurrence trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Endoscopic Resection of Large Colorectal Polyps: An Observational Cohort Study
RECRUITING
-
Association Between Exercise, Patient-Reported Outcomes, and Clinical Events in Adult Cancer Survivors
RECRUITING
-
Evaluation of Outcomes of the Triathlon Hinge Knee (THK) System
RECRUITING
-
xDRIVE for Florida-based Cancer Patients
RECRUITING · NA
-
Cold Snare Endoscopic Mucosal Resection Trial
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02800486 · 37 participants · Phase 2
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
- NCT03173937 · 37 participants · Phase 1
Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome
- NCT03295227 · 37 participants · Phase 1
Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer
- NCT03401047 · 37 participants · Early Phase 1
Study to Assess Potential Impairments in Estradiol Augmentation of Gonadotropin Secretion in Polycystic Ovary Syndrome
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI